Article 10 - Continuity of Care: What Happens When the Supply Chain Breaks
Share
Cannabis-based medicines prescribed in the UK are almost entirely imported. The domestic cultivation and processing infrastructure does not yet exist at the scale required to supply the patient population. That dependency creates a risk that the system has not adequately addressed: what happens when the supply chain breaks?
How the supply chain works
Licensed CBPM products are cultivated, processed, and tested overseas, primarily in Canada, the Netherlands, Portugal, and Australia. They are imported under Home Office licence, held by specialist wholesalers, and dispensed through licensed pharmacies to patients with a valid prescription.
Each stage of that chain has its own lead time, regulatory requirement, and potential point of failure. Import licence delays, customs issues, product quality failures, and wholesaler stock shortages can all interrupt supply. The patient at the end of the chain has no visibility of any of it until their prescription cannot be filled.
What breaks when supply fails
For a CBPM patient, a supply failure is not an inconvenience. It is a medical event. Patients prescribed cannabis-based medicines for chronic pain, epilepsy, PTSD, or other conditions are dependent on consistent supply for consistent therapeutic outcome.
Abrupt interruption to supply can cause withdrawal effects, return of symptoms, deterioration in condition, and in some cases significant distress. The clinical consequences of supply failure are not currently tracked or reported systematically. There is no national framework for managing patients through supply interruptions.
What patients are told and what they are not told
Most patients are not told at the point of prescription that their medicine is imported, that supply is not guaranteed, and that there is no formal continuity of care framework if it fails. They find out when their pharmacy cannot fulfil their repeat prescription.
At that point, the options available to the patient depend entirely on how quickly their clinic responds, whether an alternative product is available, whether their prescriber is willing to switch strain or product, and whether the pharmacy can source from a different wholesaler. None of this is standardised. None of it is fast.
Switching products is not straightforward
CBPM prescriptions are strain and product specific. A patient prescribed a particular flower product cannot simply switch to an available alternative without a new prescription. That requires clinical review, prescriber sign-off, and in some cases a new consultation. The time that process takes is time the patient is without medicine.
Even where a switch is possible quickly, the alternative product will have a different cannabinoid and terpene profile. The therapeutic effect will not be identical. For patients with well-established protocols, a forced switch is a clinical disruption, not just a logistical one.
The domestic infrastructure argument
The import dependency that creates this risk is not inevitable. The UK has licensed domestic cannabis cultivation. The regulatory framework exists. The gap is between the current scale of domestic production and the volume required to supply a growing patient population.
Licensed domestic cultivators including Caledonia Pharms, Northern Leaf, and others represent the beginning of that infrastructure. They are not yet operating at a scale that changes the supply picture for most patients. But they demonstrate that domestic production is possible within the existing regulatory framework, and that the import dependency is a policy and investment gap rather than a structural one.
Until that gap closes, import dependency remains and supply risk remains with it. Patients, clinicians, and the pharmacies serving them are all operating within a system that has not resolved this at the structural level.
What patients can do
The options available to patients are limited but worth understanding. Maintaining a small buffer stock where prescription terms and clinical guidance allow reduces the immediate impact of short supply interruptions. Knowing the name and licensed status of your medicine, your wholesaler, and the alternative products your prescriber is able to prescribe gives you more to work with when a conversation with your clinic becomes urgent.
Raising the issue of supply continuity with your prescriber before a failure occurs is worth doing. Ask what the plan is if your product becomes unavailable. The answer will tell you how prepared your clinic is to manage it.
What the system needs to address
A functional CBPM system requires a continuity of care framework that does not currently exist. Patients should be informed of supply risk at the point of prescription. Clinics should have documented protocols for managing supply failures. Pharmacies should have wholesaler relationships that provide access to alternatives. And the Home Office import licensing process should not be a routine source of delay in a system serving patients with chronic conditions.
This is not a future problem. It is a current one. Patients are experiencing supply failures now. The infrastructure to manage those failures systematically is not in place.
If you are a clinician, pharmacist, importer, or policy professional working on CBPM supply and would like to contribute to this library, we want to hear from you.
glenn@puruslumina.com